Algorae Pharmaceuticals (ASX: 1AI) achieved a key milestone in the recent June quarter, locking in a strategic partnership with the Victorian Centre for Functional Genomics (VCFG) at Melbourne’s Peter MacCallum Cancer Centre.
The partners are working on high-throughput experimental validation for 21 in silico predictions generated by the AI-enabled AlgoraeOS Version 1.0, alongside three drug combinations identified through conventional scientific methods.
They expect to release the initial pre-clinical results from the program within the next six months.
The trial is evaluating oncology-focused predictions across the brain, pancreas, breast, and prostate cancer cell lines.
It will focus on optimisation of cell growth kinetics and drug toxicity parameters, in vitro assessment of drug combination synergies and analysis of synergies across empirically-tested drug combinations, leveraging the ‘lab in the loop’ paradigm to enhance the predictive accuracy of AlgoraeOS.
Algorae said drug combinations that demonstrate synergistic inhibition of cancer cell proliferation may form the basis of novel therapeutic strategies for further investigation.
The company has steadily progressed development of its AlgoraeOS Version 2.0 during the quarter and anticipates delivery before year end, as per its previous guidance.
The 2.0 update features enhancements to improve prediction accuracy, scalability and performance.
It will include new model architecture, an object-oriented programming framework, high-performance multi-GPU processing, and multi-modality data integration.
Algorae confirmed that validation data from VCFG studies combined with cross-validation and synergy metrics would be incorporated into future platform releases for continuous improvement of predictive capabilities for synergistic drug combinations.
Algorae had a cash balance of $2.32 million at end June, supported by a research and development (R&D) rebate of $318,771 from the Australian government.
Net operating cash outflow for the quarter was $264,504, with $476,265 in R&D expenditure and $76,310 in payments to directors and related parties.
Algorae said it remained well-capitalised to achieve near-term clinical and commercial milestones, supported by robust intellectual property, strategic collaborations, and a capital-efficient AI-enabled drug discovery model.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。